Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Merck Partners DLL3 T-Cell Engager with Daiichi Sankyo

publication date: Aug 6, 2024

Daiichi Sankyo will co-develop Merck’s MK-6070, an investigational delta-like ligand 3 (DLL3) targeting T-cell engager. Merck acquired the candidate when it bought Harpoon Therapeutics in January for $670 million. Merck will receive an upfront payment of $170 million from Daiichi Sankyo; development costs and sales revenues will be split between the two companies. In 2023, Merck formed an agreement for joint development of three of Daiichi Sankyo’s DXd antibody-drug conjugate (ADC) candidates. Merck paid $4 billion upfront in the deal which had a total value of $22 billion. More details....

Share this with colleagues:  



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here